
CRDF
Cardiff Oncology Inc
Biotechnology
Cardiff Oncology Inc (CRDF) Stock News
The latest CRDF headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology announced updated Phase 2 CRDF-004 data for onvansertib, a PLK1 inhibitor, will be presented at ASCO 2026 on June 2, 2026, with an investor webcast scheduled for June 3, 2026. The company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational Phase 3 trial for first-line RAS-mutated metastatic colorectal cancer, following positive dose-dependent improvements in response rates and progression-free survival.